42C — IX Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- SG$520.60m
- SG$511.67m
- SG$6.85m
Annual cashflow statement for IX Biopharma, fiscal year end - June 30th, SGD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.6 | -9.62 | -10.8 | -10.1 | -7.99 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 6.65 | 0.933 | 2.79 | 3.9 | 0.823 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.008 | 0.093 | 0.588 | 1.62 | -1.06 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 3.12 | -7.66 | -6.55 | -3.76 | -7.51 |
| Capital Expenditures | -0.2 | -0.695 | -0.285 | -0.201 | -0.117 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -5.42 | 0 | 1.34 | 0 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -5.62 | -0.695 | 1.06 | -0.201 | -0.117 |
| Financing Cash Flow Items | -0.202 | -0.311 | -0.286 | -0.593 | -0.451 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.79 | 1.42 | 0.724 | 3.12 | 21.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.32 | -6.98 | -4.77 | -0.828 | 13.8 |